LETTER TO BLOOD| JANUARY 30, 2020
Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALLJing Pan , Shiyu Zuo , Biping Deng , Xiuwen Xu , Chuo Li , Qinlong Zheng , Zhuojun Ling , Weiliang Song , Jinlong Xu , Jiajia Duan , Zelin Wang , Xinjian Yu , Alex H. Chang , Xiaoming Feng , Chunrong Tong
Blood (2020) 135 (5): 387–391.
https://doi.org/10.1182/blood.2019003293Subjects:
Clinical Trials and Observations, Immunobiology and Immunotherapy, Lymphoid Neoplasia, Pediatric Hematology
Topics:
burkitt's lymphoma, cd19 antigens, disease remission, leukemia, b-cell, acute, child, acute lymphocytic leukemia,chimeric antigen receptors, t-cell therapy, toxic effect
TO THE EDITOR:
Trials with CD19 or CD22 chimeric antigen receptor (CAR) T-cell therapy have shown 70% to 90% complete remission (CR) rate in patients with refractory or relapsed B acute lymphoblastic leukemia (r/r B-ALL).1-4 However, a large proportion of patients with CR relapsed within 1 year.5,6 It is critical to develop new strategies to improve the durability of remission after CAR T-cell therapy, especially when patients cannot be bridged to allogeneic hematopoietic cell transplantation (allo-HCT).2 Loss or mutation of CD19 was frequently observed and considered to be a major mechanism of relapse.1,4-6 Diminished CD22 site density has been observed to be associated with relapse after CD22 CAR T-cell therapy.3 Both CD19/CD22-bispecific CAR T cells and infusion of a cocktail of CD19 and CD22 CAR T-cells have been shown to prevent leukemia antigen loss.7-12 A...
© 2020 by The American Society of HematologyThis program is developed by Focus Insight with the permission of American Society of Hematology, Inc. The content are excerpted from the journal Blood. Copyright © 2019 The American Society of Hematology. All rights reserved. 「American Society of Hematology」, 「ASH」 and the ASH Logo are registered trademarks of the American Society of Hematology.